ALUMIS INC. (ALMS) Form 10-Q — Aug 13, 2026

$ALMSForm 10-QFiled Aug 13, 2026, 4:19 PM ET0001847367-26-000018Original filing

Alumis reported a Q2 2026 net loss of $142.2 million ($1.11 per share) on total revenue of $1.7 million, with the loss burden including a $41.8 million impairment of the lonigutamab intangible asset acquired in the May 2025 ACELYRIN merger, cutting its carrying value to $9.1 million. Prior-year comparisons are distorted by a $187.9 million gain on bargain purchase recognized in Q2 2025 on the same merger. The balance sheet remains well funded: cash, cash equivalents and marketable securities stood at $502.3 million at June 30, 2026, after a January 2026 offering of roughly 20.3 million shares at $17.00 raised $324.4 million net.

Key figures

Eps: -$1.11 basic and diluted (Q2 2026); -$1.86 (six months 2026)
Revenue: $3.4 million (six months ended June 30, 2026); $1.7 million (Q2 2026)
Net Income: -$142.2 million (Q2 2026); -$235.3 million (six months ended June 30, 2026)
Total Assets: $560.6 million
Cash Position: $502.3 million (cash, cash equivalents and marketable securities as of June 30, 2026)
Shares Outstanding: 128,505,445 total (124,445,537 voting + 4,059,908 non-voting) as of June 30, 2026
Atm capacity: $300.0 million with Cantor; no shares sold as of June 30, 2026
Accumulated deficit: $1,137.2 million
Intangible impairment: $41.8 million (Q2 2026, lonigutamab IPR&D)
January 2026 offering: 20,297,500 shares at $17.00; $324.4 million net proceeds
Kaken upfront payment: $20.0 million (March 2025)
Nda submission target: Q4 2026 (envu in moderate-to-severe plaque psoriasis)
Total stockholders equity: $452.2 million
Bargain purchase gain 2025: $187.9 million
Kaken potential milestones: $36.0 million regulatory plus ¥15.5 billion commercial
Operating cash burn h1 2026: $168.6 million
Climb bio disputed milestone: $3.0 million
Acelyrin merger consideration: $238.1 million (May 21, 2025)
Stock based compensation h1 2026: $26.6 million
Lonigutamab post impairment carrying value: $9.1 million

Price after filing

1 day: +3.7%7 days: -6.3%30 days: -62.4%

Close on the filing date to close N calendar days later (from $24.41). Historical, not a forecast.

AI analysis

Red flags5 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.